Paul F Kantor

List of Publications by Year
in descending order

121 papers	6,263 citations	94269 37 h-index	74018 75 g-index
127 all docs	127 docs citations	127 times ranked	6356 citing authors

#	Article	IF	Citations
1	The genetic architecture of pediatric cardiomyopathy. American Journal of Human Genetics, 2022, 109, 282-298.	2.6	21
2	Drug Treatment of Heart Failure in Children: Gaps and Opportunities. Paediatric Drugs, 2022, 24, 121-136.	1.3	3
3	QTc and QRS Abnormalities are Associated with Outcome in Pediatric Heart Failure. Pediatric Cardiology, 2022, , .	0.6	0
4	Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors. European Heart Journal Cardiovascular Imaging, 2021, 22, 435-442.	0.5	19
5	Hypertrophic Cardiomyopathy in Adolescence. JACC: Case Reports, 2021, 3, 10-15.	0.3	2
6	Response by Mital et al to Letter Regarding Article, â€œA Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathyâ€• Circulation, 2021, 143, e788-e789.	1.6	2
7	Genetic Causes of Cardiomyopathy in Children: First Results From the Pediatric Cardiomyopathy Genes Study. Journal of the American Heart Association, 2021, 10, e017731.	1.6	29
8	2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, e23-e106.	0.4	33
9	Impact of Genetic Testing for Cardiomyopathy on Emotional Well-Being and Family Dynamics: A Study of Parents and Adolescents. Circulation Genomic and Precision Medicine, 2021, 14, e003189.	1.6	2
10	Non-invasive biomarkers of Fontan-associated liver disease. JHEP Reports, 2021, 3, 100362.	2.6	16
11	Recent and Upcoming Drug Therapies for Pediatric Heart Failure. Frontiers in Pediatrics, 2021, 9, 681224.	0.9	9
12	Self-reported and Accelerometer-Measured Physical Activity in Children With Cardiomyopathy. Journal of Cardiovascular Nursing, 2020, 35, 300-306.	0.6	3
13	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary. Journal of the American College of Cardiology, 2020, 76, 3022-3055.	1.2	394
14	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 76, e159-e240.	1.2	364
15	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy. Circulation, 2020, 142, e558-e631.	1.6	263
16	2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary. Circulation, 2020, 142, e533-e557.	1.6	181
17	Elevated Heart Rate and Survival in Children With Dilated Cardiomyopathy: A Multicenter Study From the Pediatric Cardiomyopathy Registry. Journal of the American Heart Association, 2020, 9, e015916.	1.6	8
18	A Validated Model for Sudden Cardiac Death Risk Prediction in Pediatric Hypertrophic Cardiomyopathy. Circulation, 2020, 142, 217-229.	1.6	129

#	Article	IF	Citations
19	Machine Learning Identifies Clinical andÂGenetic Factors Associated With Anthracycline Cardiotoxicity in PediatricÂCancer Survivors. JACC: CardioOncology, 2020, 2, 690-706.	1.7	16
20	Cardiac biomarkers in pediatric cardiomyopathy: Study design and recruitment results from the Pediatric Cardiomyopathy Registry. Progress in Pediatric Cardiology, 2019, 53, 1-10.	0.2	7
21	The clinical impact of donor-specific antibodies on antibody-mediated rejection and long-term prognosis after heart transplantation. Current Opinion in Organ Transplantation, 2019, 24, 245-251.	0.8	21
22	Update on pediatric heart failure. Current Opinion in Pediatrics, 2019, 31, 598-603.	1.0	9
23	Echocardiographic Assessment of Cardiac Function in Pediatric Survivors of Anthracycline-Treated Childhood Cancer. Circulation: Cardiovascular Imaging, 2019, 12, e008869.	1.3	33
24	No Obesity Paradox in Pediatric Patients With Dilated Cardiomyopathy. JACC: Heart Failure, 2018, 6, 222-230.	1.9	14
25	Genetic Evaluation of Cardiomyopathyâ€"A Heart Failure Society of America Practice Guideline. Journal of Cardiac Failure, 2018, 24, 281-302.	0.7	280
26	Remodeling of myocardial extracellular matrix and proteoglycans varies in pediatric versus adult patients with dilated cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2018, 124, 115.	0.9	0
27	Control of cardiac fatty acid metabolism in infants with hypoplastic left heart syndrome. Journal of Molecular and Cellular Cardiology, 2018, 124, 91-92.	0.9	1
28	Disparate Remodeling of the Extracellular Matrix and Proteoglycans in Failing Pediatric Versus Adult Hearts. Journal of the American Heart Association, 2018, 7, e010427.	1.6	27
29	Outpatient Management of Pediatric HF. , 2018, , 457-466.		0
30	Acetylation contributes to hypertrophy-caused maturational delay of cardiac energy metabolism. JCI Insight, 2018, 3, .	2.3	21
31	Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genetics in Medicine, 2018, 20, 899-909.	1.1	172
32	The Utility of Cardiopulmonary Exercise Testing for the Prediction of Outcomes in Ambulatory Children With Dilated Cardiomyopathy. Transplantation, 2017, 101, 2455-2460.	0.5	9
33	Abnormal Myocardial Contractility After Pediatric Heart Transplantation by Cardiac MRI. Pediatric Cardiology, 2017, 38, 1198-1205.	0.6	6
34	Ivabradine in Children With Dilated Cardiomyopathy and Symptomatic Chronic Heart Failure. Journal of the American College of Cardiology, 2017, 70, 1262-1272.	1.2	68
35	Pediatric Cardiomyopathies. Circulation Research, 2017, 121, 855-873.	2.0	207
36	Design for the sacubitril/valsartan (LCZ696) compared with enalapril study of pediatric patients with heart failure due to systemic left ventricle systolic dysfunction (PANORAMA-HF study). American Heart Journal, 2017, 193, 23-34.	1.2	58

#	Article	IF	Citations
37	Survival Without Cardiac Transplantation Among Children With DilatedÂCardiomyopathy. Journal of the American College of Cardiology, 2017, 70, 2663-2673.	1.2	59
38	Cardiac hypertrophy suppresses glucose oxidation in newborns with congenital heart defects. Journal of Molecular and Cellular Cardiology, 2017, 112, 138.	0.9	0
39	Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study. BMC Cancer, 2017, 17, 519.	1.1	25
40	Impact of Heart Transplantation on Cheyne-Stokes Respiration in a Child. Case Reports in Pediatrics, 2016, 2016, 1-3.	0.2	6
41	Prevalence and Severity of Anemia in Children Hospitalized with Acute Heart Failure. Congenital Heart Disease, 2016, 11, 622-629.	0.0	13
42	Acetylation and succinylation contribute to maturational alterations in energy metabolism in the newborn heart. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H347-H363.	1.5	70
43	Angiotensinâ€Converting Enzyme Inhibitor Initiation and Dose Uptitration in Children With Cardiovascular Disease: A Retrospective Review of Standard Clinical Practice and a Prospective Randomized Clinical Trial. Journal of the American Heart Association, 2016, 5, .	1.6	13
44	The evolution of medical therapy for children with heart failure. Progress in Pediatric Cardiology, 2016, 43, 3-6.	0.2	0
45	Pharmacokinetics/Pharmacodynamics, Efficacy and Safety of Sacubitril/Valsartan Versus Enalapril in Pediatric Patients with Heart Failure Due to Systemic Left Ventricle Systolic Dysfunction: Study Design and Rationale. Journal of Cardiac Failure, 2016, 22, S36-S37.	0.7	0
46	Acetylation Control Contributes to Maturational Alterations in Cardiac Energy Metabolism in the Newborn Heart. Journal of Cardiac Failure, 2016, 22, S199.	0.7	0
47	Cardiac Hypertrophy in Neonates With Congenital Heart Disease Delays Maturational Alterations in Cardiac Energy Metabolism by Modifying Myocardial Acetylation Control. Journal of Cardiac Failure, 2016, 22, S230-S231.	0.7	0
48	Incidence, Severity, and Association With Adverse Outcome of Hyponatremia in Children Hospitalized With Heart Failure. American Journal of Cardiology, 2016, 118, 1006-1010.	0.7	21
49	Future research directions in pediatric cardiomyopathy. Progress in Pediatric Cardiology, 2016, 40, 35-39.	0.2	1
50	Preventing pediatric cardiomyopathy: a 2015 outlook. Expert Review of Cardiovascular Therapy, 2016, 14, 321-339.	0.6	4
51	Histological validation of cardiovascular magnetic resonance T1 mapping markers of myocardial fibrosis in paediatric heart transplant recipients. Journal of Cardiovascular Magnetic Resonance, 2016, 19, 10.	1.6	64
52	Magnetic resonance imaging of the transplanted pediatric heart as a potential predictor of rejection. World Journal of Transplantation, 2016, 6, 751.	0.6	15
53	Diffuse Myocardial Fibrosis in Children After Heart Transplantations. Transplantation, 2015, 99, 2656-2662.	0.5	23
54	Cardiomyopathy Phenotypes and Outcomes for Children With Left Ventricular Myocardial Noncompaction: Results From the Pediatric Cardiomyopathy Registry. Journal of Cardiac Failure, 2015, 21, 877-884.	0.7	140

#	Article	IF	Citations
55	Comments on the Assessment of Biventricular Function in Children after Tetralogy of Fallot Repair. Journal of the American Society of Echocardiography, 2015, 28, 495-496.	1.2	0
56	Exercise Echocardiography Demonstrates Biventricular Systolic Dysfunction and Reveals Decreased Left Ventricular Contractile Reserve in Children After Tetralogy of Fallot Repair. Journal of the American Society of Echocardiography, 2015, 28, 294-301.	1.2	37
57	Activating PPARÎ± Prevents Postâ€“Ischemic Contractile Dysfunction in Hypertrophied Neonatal Hearts. Circulation Research, 2015, 117, 41-51.	2.0	60
58	Prevalence, predictors, and outcomes of cardiorenal syndrome in children with dilated cardiomyopathy: a report from the Pediatric Cardiomyopathy Registry. Pediatric Nephrology, 2015, 30, 2177-2188.	0.9	15
59	Refractory cardiogenic shock in a patient with Î²â€thalassemia major requiring mechanical circulatory support: Case report and literature review. Pediatric Transplantation, 2015, 19, E93-6.	0.5	3
60	Risk factors for mortality or delisting of patients from the pediatric heart transplant waiting list. Journal of Thoracic and Cardiovascular Surgery, 2014, 147, 462-468.	0.4	38
61	Factors Associated with Serum B-Type Natriuretic Peptide in Infants with Single Ventricles. Pediatric Cardiology, 2014, 35, 879-887.	0.6	14
62	Prognostic Implications of the Systolic to Diastolic Duration Ratio in Children With Idiopathic or Familial Dilated Cardiomyopathy. Circulation: Cardiovascular Imaging, 2014, 7, 773-780.	1.3	19
63	Spectrum and Outcome of Primary Cardiomyopathies Diagnosed During Fetal Life. JACC: Heart Failure, 2014, 2, 403-411.	1.9	36
64	Sleep-disordered Breathing in Children with Cardiomyopathy. Annals of the American Thoracic Society, 2014, 11, 770-776.	1.5	21
65	Recovery of Echocardiographic Function in Children With Idiopathic Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2014, 63, 1405-1413.	1.2	126
66	Relation of right ventricular mechanics to exercise tolerance in children after tetralogy of Fallot repair. American Heart Journal, 2013, 165, 551-557.	1.2	62
67	Newer Imaging Modalities in the Assessment of Heart Function in Single Ventricle Hearts. Canadian Journal of Cardiology, 2013, 29, 886-889.	0.8	9
68	Presentation, Diagnosis, and Medical Management of Heart Failure in Children: Canadian Cardiovascular Society Guidelines. Canadian Journal of Cardiology, 2013, 29, 1535-1552.	0.8	192
69	Mitochondrial citrate synthase crystals: Novel finding in Sengers syndrome caused by acylglycerol kinase (AGK) mutations. Molecular Genetics and Metabolism, 2013, 108, 40-50.	0.5	37
70	Determinants and functional impact of restrictive physiology after repair of tetralogy of Fallot: New insights from magnetic resonance imaging. International Journal of Cardiology, 2013, 167, 1347-1353.	0.8	35
71	Outcomes of Cardiac Transplantation in Single-Ventricle Patients With Plastic Bronchitis: A Multicenter Study. Journal of the American College of Cardiology, 2013, 61, 985-986.	1.2	44
72	Pharmacogenomics and Heart Failure in Congenital Heart Disease. Canadian Journal of Cardiology, 2013, 29, 779-785.	0.8	1

#	Article	IF	Citations
73	Heart Failure in Congenital Heart Disease. Canadian Journal of Cardiology, 2013, 29, 753-754.	0.8	15
74	Common data elements for clinical research in Friedreich's ataxia. Movement Disorders, 2013, 28, 190-195.	2.2	14
75	Sudden Death in an Infant With Angina, Restrictive Cardiomyopathy, and Coronary Artery Bridging. Circulation: Heart Failure, 2012, 5, e92-3.	1.6	11
76	Cardiac Transplantation in Friedreich Ataxia. Journal of Child Neurology, 2012, 27, 1193-1196.	0.7	11
77	Outcomes of Restrictive Cardiomyopathy in Childhood and the Influence of Phenotype. Circulation, 2012, 126, 1237-1244.	1.6	166
78	Early Predictors of Survival to and After Heart Transplantation in Children With Dilated Cardiomyopathy. Circulation, 2012, 126, 1079-1086.	1.6	71
79	Impaired right and left ventricular diastolic myocardial mechanics and filling in asymptomatic children and adolescents after repair of tetralogy of Fallot. European Heart Journal Cardiovascular Imaging, 2012, 13, 905-913.	0.5	75
80	Impaired Left Ventricular Myocardial Mechanics and Their Relation to Pulmonary Regurgitation, Right Ventricular Enlargement and Exercise Capacity in Asymptomatic Children after Repair of Tetralogy of Fallot. Journal of the American Society of Echocardiography, 2012, 25, 494-503.	1.2	68
81	Influence of RV Restrictive Physiology on LV Diastolic Function in Children after Tetralogy of Fallot Repair. Journal of the American Society of Echocardiography, 2012, 25, 866-873.	1.2	37
82	Incidence of and Risk Factors for Sudden Cardiac Death in Children With Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2012, 59, 607-615.	1.2	157
83	Isovolumic Acceleration at Rest and During Exercise in Children. Journal of the American College of Cardiology, 2011, 57, 1100-1107.	1.2	43
84	Pharmacologic therapy of heart failure in children. Pharmacological Research, 2011, 64, 427-430.	3.1	8
85	Current applications and future needs for biomarkers in pediatric cardiomyopathy and heart failure: Summary from the Second International Conference on Pediatric Cardiomyopathy. Progress in Pediatric Cardiology, 2011, 32, 11-14.	0.2	19
86	Effectiveness of Serial Increases in Amino-Terminal Proâ€“B-Type Natriuretic Peptide Levels to Indicate the Need for Mechanical Circulatory Support in Children With Acute Decompensated Heart Failure. American Journal of Cardiology, 2011, 107, 573-578.	0.7	38
87	Usefulness of Mitral Regurgitation as a Marker of Increased Risk for Death or Cardiac Transplantation in Idiopathic Dilated Cardiomyopathy in Children. American Journal of Cardiology, 2011, 107, 1517-1521.	0.7	17
88	Biomarkers in pediatric heart failure: Their role in diagnosis and evaluating disease progression. Progress in Pediatric Cardiology, 2011, 31, 53-57.	0.2	8
89	Undiagnosed Heart Disease Leading to Sudden Unexpected Death in Childhood: A Retrospective Study. Pediatrics, 2011, 128, e513-e520.	1.0	20
90	Clinical practice. European Journal of Pediatrics, 2010, 169, 269-279.	1.3	28

#	Article	IF	Citations
91	Clinical practice. European Journal of Pediatrics, 2010, 169, 403-410.	1.3	14
92	Dilated Cardiomyopathy in Epidermolysis Bullosa: A Retrospective, Multicenter Study. Pediatric Dermatology, 2010, 27, 238-243.	0.5	37
93	Hypertension after pediatric cardiac transplantation: Detection, etiology, implications and management. Pediatric Transplantation, 2010, 14, 159-168.	0.5	12
94	Exercise induces biventricular mechanical dyssynchrony in children with repaired tetralogy of Fallot. Heart, 2010, 96, 2010-2015.	1.2	49
95	Early changes in right ventricular function and their clinical consequences in childhood and adolescent dilated cardiomyopathy. Cardiology in the Young, 2010, 20, 418-425.	0.4	14
96	Ventricular Remodeling and Survival Are More Favorable for Myocarditis Than For Idiopathic Dilated Cardiomyopathy in Childhood. Circulation: Heart Failure, 2010, 3, 689-697.	1.6	128
97	The Impact of Changing Medical Therapy on Transplantation-Free Survival in Pediatric Dilated Cardiomyopathy. Journal of the American College of Cardiology, 2010, 55, 1377-1384.	1.2	110
98	Decline in rejection in the first year after pediatric cardiac transplantation: A multi-institutional study. Journal of Heart and Lung Transplantation, 2010, 29, 625-632.	0.3	77
99	Mitogenic cardiomyopathy. Human Pathology, 2010, 41, 1002-1008.	1.1	26
100	Friedreich ataxia presenting as sudden cardiac death in childhood: Clinical, genetic and pathological correlation, with implications for genetic testing and counselling. Neuromuscular Disorders, 2010, 20, 340-342.	0.3	20
101	Pathophysiology and Management of Heart Failure in Repaired Congenital Heart Disease. Heart Failure Clinics, 2010, 6, 497-506.	1.0	41
102	Noninvasive Resting Cardiac Output, but Not Resting Ejection Fraction Correlates Well with Maximal Aerobic Capacity in Children with Cardiomyopathy and Repaired Congenital Heart Disease. Journal of Cardiac Failure, 2009, 15, S106.	0.7	0
103	Exercise Capacity Improves With Time in Pediatric Heart Transplant Recipients. Journal of Heart and Lung Transplantation, 2009, 28, 585-590.	0.3	23
104	The Subpulmonary Right Ventricle in Chronic Left Ventricular Failure. , 2009, , 221-229.		0
105	Thoracoscopic ligation versus coil occlusion for patent ductus arteriosus: A matched cohort study of outcomes and cost. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 1643-1648.	1.3	19
106	Evaluation of Mechanical Dyssynchrony in Children With Idiopathic Dilated Cardiomyopathy and Associated Clinical Outcomes. American Journal of Cardiology, 2008, 101, 1191-1195.	0.7	32
107	Hypertension After Pediatric Heart Transplantation is Primarily Associated With Immunosuppressive Regimen. Journal of Heart and Lung Transplantation, 2008, 27, 501-507.	0.3	27
108	Surgical Repair of the Mitral Valve in Children With Dilated Cardiomyopathy and Mitral Regurgitation. Annals of Thoracic Surgery, 2008, 85, 2085-2088.	0.7	17

#	Article	IF	Citations
109	Left Ventricular Diastolic Mechanical Dyssynchrony and Associated Clinical Outcomes in Children With Dilated Cardiomyopathy. Circulation: Cardiovascular Imaging, 2008, 1, 50-57.	1.3	31
110	Index of Suspicion. Pediatrics in Review, 2008, 29, 399-406.	0.2	0
111	Pediatric Heart Transplantation in Human Leukocyte Antigenâ€“Sensitized Patients. Circulation, 2007, 116, I172-8.	1.6	74
112	Clinical considerations for Heart Rhythm allied professionals: Understanding heart failure in congenital heart disease patients. Heart Rhythm, 2007, 4, 248-250.	0.3	0
113	Heart transplant for pediatric cardiomyopathy. Progress in Pediatric Cardiology, 2007, 23, 67-72.	0.2	12
114	Myocardial Energy Metabolism. , 2001, , 543-569.		7
115	Characterization of rat liver malonyl-CoA decarboxylase and the study of its role in regulating fatty acid metabolism. Biochemical Journal, 2000, 350, 599.	1.7	16
116	Characterization of rat liver malonyl-CoA decarboxylase and the study of its role in regulating fatty acid metabolism. Biochemical Journal, 2000, 350, 599-608.	1.7	59
117	The Antianginal Drug Trimetazidine Shifts Cardiac Energy Metabolism From Fatty Acid Oxidation to Glucose Oxidation by Inhibiting Mitochondrial Long-Chain 3-Ketoacyl Coenzyme A Thiolase. Circulation Research, 2000, 86, 580-588.	2.0	693
118	Fatty Acid Oxidation in the Reperfused Ischemic Heart. American Journal of the Medical Sciences, 1999, 318, 3-14.	0.4	51
119	Volume overload hypertrophy of the newborn heart slows the maturation of enzymes involved in the regulation of fatty acid metabolism. Journal of the American College of Cardiology, 1999, 33, 1724-1734.	1.2	46
120	Fatty Acid Oxidation in the Reperfused Ischemic Heart. American Journal of the Medical Sciences, 1999, 318, 3.	0.4	88
121	Maturation of fatty acid and carbohydrate metabolism in the newborn heart. Molecular and Cellular Biochemistry, 1998, 188, 49-56.	1.4	95